Results 111 to 120 of about 25,866 (210)

Topotecan [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Topotecan in second-line therapy of SCLC: Impact on survival? [PDF]

, 2000
Gatzemeier, U., Gosse, H., Hruska, D., Huber, Rudolf M., Kleinschmidt, R., Mezger, J., Pawel, J. von, Saal, J. G., Steppert, C., Steppling, H.   +9 more
core   +1 more source

A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250). [PDF]

ESMO Open
Navarro A, Thomas A, Cheng Y, Chen Y, Reguart N, Yoshida T, Cousin S, Dong X, Yamamoto N, Cappuzzo F, Hallwachs R, Bolleddula J, Sarholz B, Grombacher T, Otte M, Gounaris I, Ferrer J, Moulin C, Paz-Ares L.   +18 more
europepmc   +1 more source

Stability study of topotecan in ophthalmic prefilled syringes for intravitreal delivery. [PDF]

Eur J Hosp Pharm
Bello W, Hosotte C, Stampfli C, Pierrot A, Munier FL, Berger-Gryllaki M, Pezzatti J, Carrez L, Sadeghipour F.   +8 more
europepmc   +1 more source

Role of additional topotecan injections (plus two) in reducing recurrence rate in retinoblastoma of group D and group E patients: a retrospective study. [PDF]

BMJ Open Ophthalmol
Lin X, Zheng Z, Chen H, Qian J, Liu Q, Ma R, Xue K.   +6 more
europepmc   +1 more source

Electro-encephalographic surrogate measures fail to describe the pharmacodynamic interaction between ketamine and propofol. [PDF]

, 2004
Mortier, Eric, Struys, Michel, VEREECKE, HUGO   +2 more
core   +1 more source

HIGH-DOSE INTRAVITREAL TOPOTECAN (100 µ G/0.1 CC) AS MONOTHERAPY FOR RECURRENT/REFRACTORY INTRAOCULAR RETINOBLASTOMA IN SEVEN EYES. [PDF]

Retina
Vempuluru VS, Raval V, Kaliki S.
europepmc   +1 more source

Place in therapy of key treatments for platinum-sensitive, relapsed, extensive-stage small cell lung cancer with a focus on lurbinectedin: a narrative review with case studies. [PDF]

Drugs Context
Shunyakov L, Badin FB, Hafer J, König D, Froesch P, Greillier L.   +5 more
europepmc   +1 more source

Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma. [PDF]

Sci Adv
Han JZR, Phimmachanh M, Hastings JF, Leong KH, Ng BH, Ni J, Fontaine-Titley A, Cadell AL, O'Donnell YE, Clearwater M, Kamili A, Haber M, Norris M, Timpson P, Trahair TN, Fletcher JI, Fey D, Kolch W, Latham SL, Croucher DR.   +19 more
europepmc   +1 more source

High-Risk neuroblastoma therapeutics Topotecan and 13-cis-Retinoic acid modulate autophagy and induce DNA damage response in hematopoietic stem cells and monocytes. [PDF]

Sci Rep
Lázničková P, Tidu F, Hrdý J, Boráková K, Hortová Kohoutková M, Frič J.   +5 more
europepmc   +1 more source